Evidence map›Paper›PMID 36388060›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2022

Validation of atovaquone plasma levels by liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring in pediatric patients.

Thomas D Horvath, Izmarie Poventud-Fuentes, Lily Olayinka, Asha James, Sigmund J Haidacher, Kathleen M Hoch, Alexandra M Stevens, Anthony M Haag, Sridevi Devaraj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Thomas D HorvathDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Izmarie Poventud-FuentesDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Lily OlayinkaDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Asha JamesDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Sigmund J HaidacherDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Kathleen M HochDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Alexandra M StevensDepartment of Pediatric Hematology/Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA.
Anthony M HaagDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Sridevi DevarajDepartment of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Baylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atovaquone has traditionally been used as an antiparasitic and antifungal agent, but recent studies have shown its potential as an anticancer agent. The high variability in atovaquone bioavailability highlights the need for therapeutic drug monitoring, especially in pediatric patients. The goal of our study was to develop and validate the performance of an assay to quantify atovaquone plasma concentrations collected from pediatric cancer patients using LC-MS/MS. Methods: Atovaquone was extracted from a 10 µL volume of K Results: Atovaquone and its deuterated internal standard were analyzed using a gradient chromatographic method that had an overall cycle-time of 7.4 min per injection, and retention times of 4.3 min. Atovaquone was measured over a dynamic concentration range of 0.63 - 80 µM with a deviation within ≤ ± 5.1 % of the target value. Intra- and inter-assay precision were ≤ 2.7 % and ≤ 8.4 %, respectively. Dilutional, carryover, and interference studies were also within acceptable limits. Conclusions: Our studies have shown that our LC-MS/MS-based method is both reliable and robust for the quantification of plasma atovaquone concentrations and can be used to determine the effective dose of atovaquone for pediatric patients treated for AML.

Indexed as

ACN, AcetonitrileAcute myeloid leukemiaAML, Acute Myeloid LeukemiaATF4, Activating Transcription Factor 4AtovaquoneCRR, Clinical Reportable Range(CSEH) plasma, Charcoal Stripped K2-EDTA HumanDMF, Di-Methyl FormamideeIF2α, Eukaryotic Initiation Factor 2αEtOH, EthanolFDA, Food and Drug AdministrationHPLC, High-Performance Liquid ChromatographyIPA, IsopropanolLC-MS/MSMeOH, MethanolmTOR, mammalian Target Of RapamycinPJP, Pneumocystis jirovecii pneumoniaREDD1, REgulated in Development and DNA damage responses 1STAT3, Signal Transducer and Activator of Transcription 3TDM, Therapeutic Drug Monitoring, LC-MS/MS, Liquid Chromatography-tandem Mass SpectrometryTherapeutic drug monitoringXIC, eXtracted Ion Chromatogram

Identifiers

PMID36388060
PMCPMC9641598
OpenAlexW4295647721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.